N-methyl-1-[1-(3,4-dichlorophenyl)-cyclobutyl]ethylamine. hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-1-[1-(3,4-dichlorophenyl)-cyclobutyl]ethylamine. hydrochloride
• 英文别名: 1-[1-(3,4-dichlorophenyl)cyclobutyl]-N-methylethanamine;hydrochloride
• 化学式: C₁₃H₁₇Cl₂N*ClH
• 分子量: 294.652
• InChiKey: BBKGXISLEJCPMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.44
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-[1-(3,4-二氯苯基)-环丁基]乙酮 在 盐酸 、 甲胺 作用下， 生成 N-methyl-1-[1-(3,4-dichlorophenyl)-cyclobutyl]ethylamine. hydrochloride
  参考文献：
  名称：

  Therapeutic agents

  摘要：

  化学式I的化合物##STR1##中，其中R.sub.1为C.sub.1-6烷基，C.sub.2-6烯基，C.sub.2-6炔基，C.sub.3-7环烷基，环烷基烷基或可选择取代的苯基；R.sub.2为H或C.sub.1-3烷基；R.sub.3和/或R.sub.4为H，甲酰基，C.sub.1-3烷基，C.sub.3-6烯基，C.sub.3-6炔基，C.sub.3-7环烷基或R.sub.3和R.sub.4与氮原子一起形成杂环环系统；R.sub.5和/或R.sub.6为H，卤素，CF.sub.3，C.sub.1-3烷基，C.sub.1-3烷氧基，C.sub.1-3烷硫基或R.sub.5和R.sub.6与它们连接的碳原子一起形成第二苯环，表现出治疗抑郁症的活性。公开了制备化学式I化合物的药物组合物和方法。

  公开号：

  US04522828A1

文献信息

• SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP3082782A1

  公开（公告）日：2016-10-26
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• Implantable sensors, implantable pumps and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070197957A1

  公开（公告）日：2007-08-23

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
• Electrical devices and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070198063A1

  公开（公告）日：2007-08-23

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.